Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wolfe Research Downgrades Aptiv to Peer Perform

Wolfe Research Downgrades Aptiv to Peer Perform

Wolfe Research analyst Rod Lache downgrades Aptiv (NYSE:APTV) from Outperform to Peer Perform.

byBenzinga Newsdesk

February 3, 2023

1 minute read

Wolfe Research analyst Rod Lache downgrades Aptiv (NYSE:APTV) from Outperform to Peer Perform.

Raymond James Maintains Strong Buy on Integral Ad Science, Raises Price Target to $17

By Benzinga Newsdesk

March 3, 8:19 AM

Raymond James analyst Andrew Marok maintains Integral Ad Science (NASDAQ:IAS) with a Strong Buy and raises the price target from $12 to $17.

IAS

News

CI Financial Confirms Intent To Voluntarily Delist From The NYSE And Deregister With The U.S. Securities And Exchange Commission

By Benzinga Newsdesk

December 30, 8:02 AM

CI Financial Corp. (TSX:CIX, NYSE:CIXX) (“CI”) announced today that it has submitted a formal notice to the New York Stock Exchange (“NYSE”) of its decision to voluntarily delist its common shares

CIXX

New Four Year Data For Roche’s Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients

By Vandana Singh

March 20, 11:16 AM

Roche Holdings AG (OTC:RHHBY) announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with…

RHHBF

Analyst Ratings

A Glimpse Into The Expert Outlook On e.l.f. Beauty Through 5 Analysts

By Benzinga Insights

January 22, 8:00 AM

5 analysts have expressed a variety of opinions on e.l.f. Beauty (NYSE:ELF) over the past quarter, offering a…

ELF

Wolfe Research Downgrades Aptiv to Peer Perform

Related Posts

Raymond James Maintains Strong Buy on Integral Ad Science, Raises Price Target to $17

CI Financial Confirms Intent To Voluntarily Delist From The NYSE And Deregister With The U.S. Securities And Exchange Commission

New Four Year Data For Roche’s Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients

A Glimpse Into The Expert Outlook On e.l.f. Beauty Through 5 Analysts